Strong Biopharma Appetite Aids Solid Korean IPO Debuts
This article was originally published in PharmAsia News
Executive Summary
Shares of Green Cross LabCell and ST Pharm jumped on their debut following their successful initial public offerings earlier this month. Numerous South Korean biotechs are seeking IPOs this year amid the government's ongoing drive to nurture the biopharma sector and the stock exchange's efforts to ease listing regulations to help fund raising by promising small firms including bioventures.
You may also be interested in...
Korea Govt Partners With J&J To Bring In Local JLABS Site
In collaboration with the national health ministry, J&J’s JLAB program is coming to South Korea as its third destination in Asia, underscoring the country’s increasing need to access multinationals’ know-how and its growing impact on the global biotech landscape and innovation.
Could ASEAN Become Next Priority For Korean Pharma Firms?
Southeast Asia has so far not been a priority market for South Korean pharma firms, largely because of challenges such as access and affordability for patients. But a Deloitte executive suggested at a recent seminar that technology-based medicines, for example using next-generation formulation technologies, could be an initial focus for Korean firms looking to enter the rapidly growing ASEAN grouping.
Korean Biotech Roundup: String Of Positive R&D Developments Outweighs Some Setbacks
The South Korean biotech space has been marked by multiple positive R&D developments and pipeline and partnering progress in recent months, more than outweighing some other setbacks for the rapidly developing sector.